Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Investing.com -- Whitehawk Therapeutics Inc (NASDAQ:WHWK) stock surged 67% following the announcement of a multi-year collaboration with Tempus AI, Inc. (NASDAQ:TEM) to advance biomarker-driven research for its oncology pipeline.
The partnership will leverage Tempus’ proprietary real-world dataset to support Whitehawk’s development of antibody drug conjugates (ADCs) for cancer treatment. Whitehawk will use Tempus’ de-identified multimodal database to refine clinical trial designs by identifying patient populations with demonstrated unmet needs.
The collaboration focuses on Whitehawk’s ADC portfolio, which includes three assets targeting clinically validated proteins (PTK7, MUC16 and SEZ6) expressed in cancer indications such as lung and gynecological cancers.
"A proactive approach to our biomarker strategy ensures our programs are guided by data-driven insights," said Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics. "By partnering with Tempus, our goal is to better understand the expression of our ADC protein targets to inform indication prioritization for our clinical development programs and better exploit the full potential of our pipeline."
Ryan Fukushima, Chief Operating Officer at Tempus, noted that the combination of Tempus’ multimodal data with Whitehawk’s ADC expertise creates "a powerful foundation to validate the potential of their portfolio in a promising class of targeted cancer therapeutics."
The companies will also work to establish concordance between RNA and IHC expression of targets, potentially enhancing patient identification capabilities for ADC therapies through more objective and scalable RNA testing methods.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.